SynAct Pharma AB (OSTO:SYNACT) Volatility: 56.52% (As of Jun. 25, 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
18 GF Score
Price kr15.06
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Volatility?

SynAct Pharma AB OSTO:SYNACT -0.92% 18 Volatility is 56.52% as of Jun. 25, 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), SynAct Pharma AB's Volatility is 56.52%.

SynAct Pharma AB  (OSTO:SYNACT) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

SynAct Pharma AB Volatility Related Terms

OSTO:SYNACT vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, SynAct Pharma AB's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynAct Pharma AB Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Volatility distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Volatility falls into.


OSTO:SYNACT
18GF Score
SynAct Pharma AB OSTO:SYNACT
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB  (OSTO:SYNACT) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 56.52% mean?
SynAct Pharma AB (OSTO:SYNACT) has a Volatility of 56.52% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's Volatility too high?
SynAct Pharma AB's current Volatility is 56.52%. Overall, SynAct Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Volatility compare to VRTX and REGN?
SynAct Pharma AB's Volatility of 56.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current Volatility is 56.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current Volatility of 56.52%. The current Volatility is 56.52%. SynAct Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current Volatility is 56.52% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
18GF Score

Get the complete analysis for OSTO:SYNACT

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.06
Price